Inhibition of SAPK2/p38 enhances sensitivity to mTORC1 inhibition by blocking IRES-mediated translation initiation in glioblastoma

Molecular Cancer Therapeutics

Volumn 10, Issue 12, 2011, Pages 2244-2256

  Cloninger, Cheri ^a   Bernath, Andrew ^a   Bashir, Tariq ^a   Holmes, Brent ^a   Artinian, Nicholas ^a   Ruegg, Teresa ^a   Anderson, Lauren ^a   Masri, Janine ^a   Lichtenstein, Alan ^a,b   Gera, Joseph ^a,b,c  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CYCLIN D1; ENZYME INHIBITOR; LY 2228820; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MYC PROTEIN; PROTEIN KINASE B; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME INHIBITION; GENETIC TRANSCRIPTION; GLIOBLASTOMA; IN VITRO STUDY; INTERNAL RIBOSOME ENTRY SITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION; TRANSLATION INITIATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BINDING SITES; BRAIN NEOPLASMS; CELL LINE, TUMOR; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-1; GENES, MYC; GLIOBLASTOMA; HUMANS; MICE; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASE 11; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN BIOSYNTHESIS; PROTEIN KINASE INHIBITORS; PROTEINS; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 83355166907     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0478     Document Type: Article

References (41)

1. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007;21:2683-710. (Pubitemid 350070717)
2. Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol 2010;67:279-83.
3. Akhavan D, Cloughesy TF, Mischel PS. mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol 2010;12:882-9.
4. Kurmasheva RT, Huang S, Houghton PJ. Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer 2006;95:955-60. (Pubitemid 44606818)
5. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006;25:6436-46. (Pubitemid 44582287)
6. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001;98:10314-9. (Pubitemid 32803017)
7. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22. (Pubitemid 47001784)
8. Shi Y, Gera J, Hu L, Hsu JH, Bookstein R, Li W, et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2002;62:5027-34. (Pubitemid 34984430)
9. Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2004;279:2737-46. (Pubitemid 38114263)
10. Shi Y, Sharma A, Wu H, Lichtenstein A, Gera J. Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway. J Biol Chem 2005;280:10964-73. (Pubitemid 40418398)
11. Martin J, Masri J, Cloninger C, Holmes B, Artinian N, Funk A, et al. Phosphomimetic substitution of heterogeneous nuclear ribonucleoprotein A1 at serine 199 abolishes AKT-dependent internal ribosome entry site-transacting factor (ITAF) function via effects on strand annealing and results in mammalian target of rapamycin complex 1 (mTORC1) inhibitor sensitivity. J Biol Chem 2011;286:16402-13.
12. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J 2010;429:403-17.
13. Arthur JS. MSK activation and physiological roles. Front Biosci 2008;13:5866-79.
14. Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 2011;75:50-83.
15. Subkhankulova T, Mitchell SA, Willis AE. Internal ribosome entry segment-mediated initiation of c-Myc protein synthesis following genotoxic stress. Biochem J 2001;359:183-92. (Pubitemid 32939220)
16. Jo OD, Martin J, Bernath A, Masri J, Lichtenstein A, Gera J. Heterogeneous nuclear ribonucleoprotein A1 regulates cyclin D1 and c-myc internal ribosome entry site function through Akt signaling. J Biol Chem 2008;283:23274-87.
17. Masri J, Bernath A, Martin J, Jo OD, Vartanian R, Funk A, et al. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res 2007;67:11712-20.
18. Chou T, Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 1983;4:450-4.
19. Teicher BA. Tumor models for efficacy determination. Mol Cancer Ther 2006;5:2435-43. (Pubitemid 44650906)
20. Dodd RD. The Unfolded Protein Response: an ER-directed mechanism for translational control in cellular culture and brain tumors [PhD dissertation]. Durham, NC: Duke University; 2007.
21. Kohn AD, Barthel A, Kovacina KS, Boge A, Wallach B, Summers SA, et al. Construction and characterization of a conditionally active version of the serine/threonine kinase Akt. J Biol Chem 1998;273:11937-43. (Pubitemid 28272103)
22. Chen RQ, Yang QK, Lu BW, Yi W, Cantin G, Chen YL, et al. CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 2009;69:2663-8.
23. Osman B, Doller A, Akool el S, Holdener M, Hintermann E, Pfeilschifter J, et al. Rapamycin induces the TGFbeta1/Smad signaling cascade in renal mesangial cells upstream of mTOR. Cell Signal 2009;21:1806-17.
24. Liao Y, Hung MC. Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis. Mol Cell Biol 2003;23:6836-48. (Pubitemid 37214654)
25. Gratton JP, Morales-Ruiz M, Kureishi Y, Fulton D, Walsh K, Sessa WC. Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells. J Biol Chem 2001;276:30359-65.
26. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004;23:3151-71. (Pubitemid 38638827)
27. Huang S, Shu L, Dilling MB, Easton J, Harwood FC, Ichijo H, et al. Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol Cell 2003;11:1491-501. (Pubitemid 36776536)
28. Ishitsuka K, Hideshima T, Neri P, Vallet S, Shiraishi N, Okawa Y, et al. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol 2008;141:598-606. (Pubitemid 351667613)
29. Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A 2004;101:3130-5. (Pubitemid 38327746)
30. Brancho D, Tanaka N, Jaeschke A, Ventura JJ, Kelkar N, Tanaka Y, et al. Mechanism of p38 MAP kinase activation in vivo. Genes Dev 2003;17:1969-78. (Pubitemid 36999324)
31. Alonso G, Ambrosino C, Jones M, Nebreda AR. Differential activation of p38 mitogen-activated protein kinase isoforms depending on signal strength. J Biol Chem 2000;275:40641-8. (Pubitemid 32064705)
32. Huang S, Shu L, Easton J, Harwood FC, Germain GS, Ichijo H, et al. Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. J Biol Chem 2004;279:36490-6. (Pubitemid 39128990)
33. Zhang R, Luo D, Miao R, Bai L, Ge Q, Sessa WC, et al. Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis. Oncogene 2005;24:3954-63. (Pubitemid 40896407)
34. Kim AH, Khursigara G, Sun X, Franke TF, Chao MV. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol 2001;21:893-901. (Pubitemid 32104737)
35. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35. (Pubitemid 34155123)
36. Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP, et al. Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther 2010;9:101-12.
37. Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006;10:159-70. (Pubitemid 44175906)
38. Yamagiwa Y, Marienfeld C, Meng F, Holcik M, Patel T. Translational regulation of x-linked inhibitor of apoptosis protein by interleukin-6: a novel mechanism of tumor cell survival. Cancer Res 2004;64:1293-8. (Pubitemid 38235596)
39. Allera-Moreau C, Delluc-Clavieres A, Castano C, Van den Berghe L, Golzio M, Moreau M, et al. Long term expression of bicistronic vector driven by the FGF-1 IRES in mouse muscle. BMC Biotechnol 2007;7:74.
40. Dominguez C, Powers DA, Tamayo N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel 2005;8:421-30. (Pubitemid 40921741)
41. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 2002;9:268-72. (Pubitemid 34289898)